ALX Oncology secures up to $100M non-dilutive loan facility with Oxford and SVB, extends cash runway to mid-2025

ALX ONCOLOGY HOLDINGS INC

Initial draw of $10M from first $50M tranche; remaining $40M available through end of 2023.
Up to $50M additional in three tranches: $12.5M each tied to milestones for evorpacept and preclinical candidate, $25M at lenders' discretion.
Interest-only period of 36 months (extendable to 48); total term 59 months; no warrants or financial covenants.
Matures October 2027; floating SOFR-based interest rate with minimum 8.58% per annum.
Proceeds support evorpacept development and general working capital, extending cash runway to mid-2025.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ALX ONCOLOGY HOLDINGS INC entered into Loan and Security Agreement with Oxford Finance LLC and Lenders valued at up to $100 million aggregate principal amount, with $10 million initial funding (effective 2022-10-27).

Action: entry
Agreement: credit facility
Counterparty: Oxford Finance LLC and Lenders
Value: up to $100 million aggregate principal amount, with $10 million initial funding
Effective: 2022-10-27

Exact text from the filing

On October 27, 2022, ALX Oncology Holdings Inc., a Delaware corporation (the “Company”), entered into a loan and security agreement (the “Loan Agreement”) among Oxford Finance LLC, as collateral agent (“Agent”), and Oxford Finance LLC, Oxford Finance Credit Fund II LP, and Silicon Valley Bank, as the lenders from time to time party thereto (“Lenders”), ALX Oncology Inc., a Delaware corporation (“ALX”), Alexo Therapeutics International, an exempted company incorporated with limited liability under the laws of the Cayman Islands (“Alexo”), and Sirpant Therapeutics, an exempted company incorporated with limited liability under the laws of the Cayman Islands (“Sirpant” and, together with ALX and Alexo, the “Borrowers”), and the Company as a guarantor.

View on SEC.gov

Browse all material agreements →

ALX ONCOLOGY HOLDINGS INC filing history →

Source: SEC EDGAR

accession 0000950170-22-020521

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.